Cargando…
Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis
BACKGROUND: There are few studies evaluating long-term glycemic control using a dipeptidyl peptidase-4 inhibitor in type 2 diabetes patients with end-stage renal disease (ESRD). The aim of this study was to evaluate the safety and efficacy of vildagliptin therapy over 2 years in type 2 diabetes with...
Autores principales: | Mera, Jun-ichiro, Okada, Eiko, Okuda, Masumi, Ota, Tatsuru, Sibata, Shigeru, Uchida, Shunya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635589/ https://www.ncbi.nlm.nih.gov/pubmed/26550558 http://dx.doi.org/10.1186/s40200-015-0214-6 |
Ejemplares similares
-
Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management
por: Shibata, Shigeru, et al.
Publicado: (2021) -
Efficacy and tolerability of vildagliptin in type 2 diabetic patients on hemodialysis
por: Kume, Shinji, et al.
Publicado: (2012) -
Remission of Refractory Ascites and Discontinuation of Hemodialysis after Additional Rituximab to Long-term Glucocorticoid Therapy in a Patient with TAFRO Syndrome
por: Tsurumi, Hanako, et al.
Publicado: (2018) -
Vildagliptin is Effective for Glycemic Control in Diabetic Patients Undergoing either Hemodialysis or Peritoneal Dialysis
por: Ito, Hiroyuki, et al.
Publicado: (2013) -
Discontinuation of Hemodialysis in a Patient with Anti-GBM Disease by the Treatment with Corticosteroids and Plasmapheresis despite Several Predictors for Dialysis-Dependence
por: Fujigaki, Yoshihide, et al.
Publicado: (2017)